StreetInsider.com News Articles

Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference

Thu, 15 Oct 2026 07:00:00 -0400

CRANBURY, N.J.--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today announced that the company will attend Chardan’s 10th Annual Healthcare Conference. The company will participate in a panel on Tuesday, October 20, 2026, at 11:30 AM ET and host investor meetings.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated commercial-stage biotechnology company developing genetic medicines for rare and life-threatening diseases, with a strategic focus on inherited cardiovascular disorders and additional programs in

Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference

Thu, 15 Oct 2026 07:00:00 -0400

About Rocket Pharmaceuticals, Inc.

Goldman Sachs Upgrades Rocket Pharmaceuticals (RCKT) to Neutral

Thu, 08 Oct 2026 01:30:27 -0400

Goldman Sachs analyst Richard Law upgraded Rocket Pharmaceuticals (NASDAQ: RCKT) from Sell to Neutral with a price target of $4.00 (from $3.00).

The analyst comments: “On Tuesday (10/6), RCKT provided a comprehensive update on RP-A501 in Danon disease (DD). The updates include: 1) longer-term Ph. 1 results showing disease reversal or stabilization up to 7 years after treatment; 2) preliminary efficacy results from the first four Ph. 2 patients treated before the recalibrated dose that further supported RP-A501’s efficacy; 3) safety findings for the three patients treated at the recalibrated dose with optimized immunomodulation therapies. All patients completed their initial observation

Goldman Sachs Upgrades Rocket Pharmaceuticals (RCKT) to Neutral

Thu, 08 Oct 2026 01:30:27 -0400

Goldman Sachs analyst Richard Law upgraded Rocket Pharmaceuticals (NASDAQ: RCKT) from Sell to Neutral with a price target of $4.00 (from $3.00).

Rocket Pharmaceuticals updates RP-A501 Danon disease trial data

Wed, 07 Oct 2026 09:36:18 -0400

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) released updated clinical findings for its gene therapy candidate RP-A501, targeting Danon disease, following an investor webinar held October 6.

The company outlined the structure of its FDA-aligned pivotal Phase 2 trial, which requires 12 male patients receiving commercial-grade RP-A501 at a recalibrated dose. Trial success depends on at least seven patients meeting two co-primary endpoints at 12 months: myocardial LAMP2 protein expression of at least Grade 1 and a reduction in left ventricular mass index of at least 10% from baseline. These endpoints are intended to support a potential accelerated approval pathway.

The first three patients

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

Wed, 07 Oct 2026 09:36:00 -0400

CRANBURY, N.J.--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, highlighted key findings and development milestones presented during its October 6 Danon disease investor webinar. The update outlined a defined path to completing the FDA-aligned pivotal Phase 2 trial, highlighted sustained biological activity in longer-term Phase 1 follow-up and reported encouraging initial safety observations in the first three patients treated under the modified protocol.

Key highlights included:

Pivotal Phase 2 trial: The FDA-aligned pivotal efficacy population includes 12 male patients receiving commercial-grade

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

Wed, 07 Oct 2026 09:36:00 -0400

CRANBURY, N.J.--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, highlighted key findings and development milestones presented during its October 6 Danon disease investor webinar. The update outlined a defined path to completing the FDA-aligned pivotal Phase 2 trial, highlighted sustained biological activity in longer-term Phase 1 follow-up and reported encouraging initial safety observations in the first three patients treated under the modified protocol.

Key highlights included:

Pivotal Phase 2 trial: The FDA-aligned pivotal efficacy population includes 12 male patients receiving commercial-grade

Rocket Pharmaceuticals (RCKT) Reiterated at Overweight by Cantor Fitzgerald After Update on RP-A501

Wed, 07 Oct 2026 06:59:33 -0400

Cantor Fitzgerald analyst Josh Schimmer reiterated an Overweight rating and $15.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT).

The analyst commented, "After the close, RCKT hosted a comprehensive update on RP-A501 (AAV9 gene therapy) for Danon disease, providing additional detail on the pivotal path, patient identification efforts, and the potential commercial opportunity. Investors have had questions about both the safety profile of RP-A501 as well as the disease prevalence. With the recalibrated dose starting to show an acceptable safety profile and with today's update indicating robust progress identifying patients, the company is well on its way to addressing investors' concerns, as

Rocket Pharmaceuticals (RCKT) PT Lowered to $2.95 at Jefferies

Wed, 07 Oct 2026 04:49:15 -0400

Jefferies analyst Andrew Tsai lowered the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $2.95 (from $4.25) while maintaining a Hold rating.

The analyst comments "Several (+) updates on RP-A501's (AAV9 gene therapy) pivotal Phase II Danon program: (1) To support an accelerated approval (AA), only N=7/12 of Cohort 4 pts (58%) need to meet the 12-month co-primary endpoints - favorable as Phase I saw a 100% success rate. (2) N=3 pts in Cohort 4 have been dosed (no safety issues). The remaining N=9 will be dosed by mid-2027, placing data by mid-2028. (3) RCKT's patient-finding efforts make our $500M+ sales

Rocket Pharmaceuticals (RCKT) PT Lowered to $2.95 at Jefferies

Wed, 07 Oct 2026 04:49:15 -0400

Jefferies analyst Andrew Tsai lowered the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $2.95 (from $4.25) while maintaining a Hold rating.

Form 8-K ROCKET PHARMACEUTICALS, For: Sep 30

Tue, 06 Oct 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20261006/27156363.html

Rocket Pharmaceuticals secures $150M credit facility with Hercules Capital

Tue, 06 Oct 2026 16:12:14 -0400

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) has entered into a credit facility agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $150 million, according to a company press release.

Rocket received $35 million at closing. An additional $35 million may be drawn at the company's option during specified periods, subject to terms and conditions. A further $30 million may become available upon achievement of a specified clinical milestone related to its Danon disease program, and an additional $50 million is subject to Hercules' investment committee approval.

The facility carries an initial 30-month interest-only period and a 48-month maturity, with extensions available upon

Rocket Pharmaceuticals secures $150M credit facility with Hercules Capital

Tue, 06 Oct 2026 16:12:14 -0400

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) has entered into a credit facility agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $150 million, according to a company press release.

The facility carries an initial 30-month interest-only period and a 48-month maturity, with extensions available upon

Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital

Tue, 06 Oct 2026 16:12:00 -0400

CRANBURY, N.J.--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today announced that it has entered into a credit facility agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $150 million. The facility strengthens Rocket’s financial position and provides access to additional capital to support execution of its pivotal Phase 2 study of RP-A501 for Danon disease and continued advancement of its broader cardiovascular pipeline.

“Building on the sale of our priority review voucher, this financing

Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital

Tue, 06 Oct 2026 16:12:00 -0400

“Building on the sale of our priority review voucher, this financing

Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital

Tue, 06 Oct 2026 16:12:00 -0400

“Building on the sale of our priority review voucher, this financing

Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital

Tue, 06 Oct 2026 16:12:00 -0400

“Building on the sale of our priority review voucher, this financing

Needham Upgrades Rocket Pharmaceuticals (RCKT) to Buy

Wed, 16 Sep 2026 06:16:07 -0400

Needham analyst Gil Blum upgraded Rocket Pharmaceuticals (NASDAQ: RCKT) from Hold to Buy, PT $9.00.

For an analyst ratings summary and ratings history on Rocket Pharmaceuticals click here. For more ratings news on Rocket Pharmaceuticals click here.

Shares of Rocket Pharmaceuticals closed at $3.41 yesterday.

Needham Upgrades Rocket Pharmaceuticals (RCKT) to Buy

Wed, 16 Sep 2026 06:16:07 -0400

Needham analyst Gil Blum upgraded Rocket Pharmaceuticals (NASDAQ: RCKT) from Hold to Buy, PT $9.00.

For an analyst ratings summary and ratings history on Rocket Pharmaceuticals click here. For more ratings news on Rocket Pharmaceuticals click here.

Shares of Rocket Pharmaceuticals closed at $3.41 yesterday.

Form 4 ROCKET PHARMACEUTICALS, For: Sep 11 Filed by: Wilson Martin

Tue, 15 Sep 2026 20:28:00 -0400

si-local-file:///var/storage/secattach/20260915/27066227.html

Form 144 ROCKET PHARMACEUTICALS, Filed by: Militello John

Tue, 15 Sep 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260915/27065531.html

Form 8-K ROCKET PHARMACEUTICALS, For: Sep 15

Tue, 15 Sep 2026 07:07:00 -0400

si-local-file:///var/storage/secattach/20260915/27061033.html

FDA backs Rocket Pharmaceuticals' Danon disease trial path

Tue, 15 Sep 2026 07:00:24 -0400

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announced that the U.S. Food and Drug Administration has confirmed key elements of the company's pivotal Phase 2 trial of RP-A501, a gene therapy candidate for Danon disease, according to a press release.

The FDA confirmed a pivotal efficacy population of 12 male patients to be treated with RP-A501 at a recalibrated dose of 3.8 × 10¹³ genome copies per kilogram using commercial-grade product. The first three patients already treated under a modified protocol count toward that 12-patient total, leaving nine additional patients to be enrolled. Rocket expects to complete dosing of the remaining patients by

Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease

Tue, 15 Sep 2026 07:00:00 -0400

FDA confirms pivotal efficacy population of 12 patients, including the first three treated under the modified protocol

FDA review of initial safety data supports continued enrollment and dosing under modified protocol

FDA confirms established 12-month co-primary endpoints intended to support potential accelerated approval

Comprehensive Danon disease program webinar planned for October 6, 2026, at 4:30 p.m. ET

Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease

Tue, 15 Sep 2026 07:00:00 -0400

FDA confirms pivotal efficacy population of 12 patients, including the first three treated under the modified protocol

FDA review of initial safety data supports continued enrollment and dosing under modified protocol

FDA confirms established 12-month co-primary endpoints intended to support potential accelerated approval

Comprehensive Danon disease program webinar planned for October 6, 2026, at 4:30 p.m. ET